End stage kidney disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention: Pentoxifylline tablet 400 mg every nights for 3 month. Intervention 2: Control: usual supervision.
Sponsors
Vice Chancellor for research of Yasuj University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged>18 years Patients who were dialysed at least three times per week for a 3 month period Presence of well vascular access Written and conscious satisfaction
Exclusion criteria
Exclusion criteria: Liver disease, malignancy, AIDS Patients who have active infectious disease in previous 2 month Allergy to pentoxifylline and other methylxanthines Kidney transplantation Blood disorders Cardiac arrhythmia Hypotention Taking NSAID and steroids Immune deficiency; Taking pentoxifylline in previous 3 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-6. Timepoint: before intervention and 3 months after intervention. Method of measurement: ELISA.;IL-10. Timepoint: before intervention and 3 months after intervention. Method of measurement: ELISA.;TNF-a. Timepoint: before intervention and 3 months after intervention. Method of measurement: ELISA.;CRP. Timepoint: before intervention and 3 months after intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug reaction. Timepoint: 3 months after intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMoslem Sedaghattalab
Yasuj University of Medical Sciences
Outcome results
None listed